



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

June 25, 2024: 6:00 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**

- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:35 - 6:50**

- **Chief Medical Officer Updates** **6:50 - 7:00**

- **Follow-up Items from Previous Meetings** **7:00 – 7:00**
 - None at this time.

- **RetroDUR/ProDUR** **7:00- 7:00**
 - None at this time.

- **Clinical Update: Drug Reviews** **7:00-7:15**
(Public comment prior to Board action)

- **Biosimilar Drug Reviews**
(Criteria will be discussed with Cytokine Modulator class)
 - Simlandi® (adalimumab-ryvk)
 - Tyenne® (tocilizumab-aazg)

- **Full New Drug Reviews**
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - Voquezna® (vonoprazan)

- **New Managed Therapeutic Drug Classes** **7:15 -7:15**
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **7:15 - 8:30**
(Public comment prior to Board action)
 - Antibiotics, Topical
 - Antibiotics, Vaginal
 - Anticoagulants
 - Anticonvulsants (included Motpoly XR™ (lacosamide))
 - Antidepressants, Other (included Zurzuvae™ (zuranolone))
 - Antidepressants: SSRIs
 - Anti-Parkinson’s Agents

- Cytokine & CAM Antagonists (included Bimzelx[®] (bimekizumab-bkzx), Zymfentra[™] (infliximab-dyyb), Omvoh[™] (mirikizumab-mrkz), Velsipity[™] (etrasimod))
 - Sickle Cell Anemia (included Casgevy[™] (exagamglogene autotemcel), Lyfgenia[™] (lovotibeglogene autotemcel))
 - Stimulants & Related Agents
 - Vaginal Antifungals
-
- **Review of Newly Developed/Revised Criteria** **8:30 - 8:30**
 (Public comment prior to Board action)
 - None at this time.

 - **General Announcements** **8:30 – 8:30**
 - None at this time.

 - **Adjourn** **8:30pm**